TEMNasdaqServices-Computer Programming, Data Processing, Etc.Fiscal year ends December 31
Tempus AI, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$64.34−0.38 (-0.59%)
Close on Oct 19, 2026
- Market cap
- $11.74M
- P/E (TTM)
- –
- Dividend yield
- –
Tempus AI, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics [Member] | $289.33M | $261.10M | – | – | $241.84M | $193.80M | – | – | – | – | – | – | 75.6% | +19.6% |
| Data and applications [Member] | $93.15M | $87.02M | – | – | $72.79M | $61.93M | – | – | – | – | – | – | 24.4% | +28.0% |
| Insights Product [Member] | $77.70M | $71.30M | $82.00M | $69.00M | $57.20M | $49.50M | $64.70M | $50.10M | $40.70M | $31.30M | $38.90M | $26.90M | 20.3% | +35.8% |
| Trials Product [Member] | $9.00M | $9.90M | $9.80M | $9.20M | $9.80M | $9.70M | $10.60M | $10.10M | $10.50M | $11.30M | $14.10M | $10.60M | 2.4% | -8.2% |
| Next Product [Member] | $6.30M | $5.70M | – | – | $5.70M | $2.70M | – | – | – | – | – | – | 1.6% | +10.5% |
| Genomics [Member] | – | – | – | $252.88M | $241.84M | $193.80M | $120.43M | $116.42M | $112.32M | $102.57M | $92.23M | $96.82M | – | – |
| Data and services [Member] | – | – | – | $81.33M | $72.79M | $61.93M | $80.25M | $64.51M | $53.65M | $43.25M | $55.50M | $39.24M | – | – |
| Data And Other [Member] | – | – | – | $81.30M | $72.80M | $61.90M | – | $64.50M | $53.60M | $43.30M | – | $39.20M | – | – |
| Genomics Product [Member] | – | – | – | $252.90M | $241.80M | $193.80M | $120.40M | $116.40M | $112.30M | $102.60M | $92.20M | $96.80M | – | – |
By region
From the segment and revenue-disaggregation notes of Tempus AI's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.